StockTipsArenaBeta

BUY Anthem Biosciences Limited — BOB Capital Markets

BUYAnthem Biosciences Limited
Anthem Biosciences share price target & all analyst calls

byBOB Capital MarketsHorizon: NA (inferred 1 year)27 Feb 2026via Institutional / Brokerage Research

Entry₹701.25Inferred
Target₹835
Total upside +19.07% (call closed)
Stop lossNot given
Exit₹8354 Aug 2026, 12:08 pm
Target hit+19.07%0.00%upside left
Follow BOB Capital Markets for new calls(63% target hit, 357 closed calls)Get alertsWatch ANTHEM for new buy/sell callsGet alertsSee 4 active Long-term calls on ANTHEMSee 211 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 4 Aug 2026
3 supporting6 neutral1 opposing
Supports the BUY call (3)

1 advisor has an active short-term BUY call on this stock

Advisor consensus · adjacent horizon·9 Jul · 4w ago

1 other SEBI-registered advisor has an active long-term BUY call on this stock

Advisor consensus · same horizon·9 Jul · 4w ago

Neutral / worth noting (6)

Anthem Biosciences Limited has revised its press release regarding the unaudited consolidated financial results for the quarter ended June 30, 2026. The revised release supersedes the previous one.

BSE · Company Update·21 Jul · 2w ago

(opens in new tab)

Anthem Biosciences Limited announced its unaudited consolidated financial results for the quarter ended June 30, 2026. The company reported revenue from operations of ₹4,182 Mn and profit after tax of

BSE · Company Update·21 Jul · 2w ago

(opens in new tab)

Anthem Biosciences Limited announced the outcome of its Board Meeting held on July 21, 2026. The Board approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 3

BSE · Board Meeting·21 Jul · 2w ago

(opens in new tab)

Anthem Biosciences Limited announced the approval of its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the Limited Review Report of the Statut

NSE · Outcome of Board Meeting·21 Jul · 2w ago

(opens in new tab)
Weighs against the BUY call (1)

Anthem Biosciences Q1 Results: Shares fall over 7% as delayed deliveries drag earnings

NewsCnbc-Tv18·22 Jul · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Anthem Biosciences

All analyst calls on Anthem Biosciences

More from BOB Capital Markets

Every call and its outcome